Gastrin-releasing peptide receptor RC-3095 Fibroblasts-like synoviocyte Rheumatoid arthritis PI3K/AKT pathway A B S T R A C T Rheumatoid arthritis (RA) is an autoimmune disease that leads to joint destruction. The fibroblast-like synoviocytes (FLS) has a central role on the disease pathophysiology. The present study aimed to examine the role of gastrin-releasing peptide (GRP) and its receptor (GRPR) on invasive behavior of mice fibroblast-like synoviocytes (FLS), as well as to evaluate GRP-induced signaling on PI3K/AKT pathway. The expression of GRPR in FLS was investigated by immunocytochemistry, western blot (WB) and qRT-PCR. The proliferation and invasion were assessed by SRB and matrigel-transwell assay after treatment with GRP and/or RC-3095 (GRPR antagonist), and/or Ly294002 (inhibitor of PI3K/AKT pathway). Finally, AKT phosphorylation was assessed by WB. GRPR protein was detected in FLS and the exposure to GRP increased FLS invasion by nearly two-fold, compared with untreated cells (p < 0.05), while RC-3095 reversed that effect (p < 0.001). GRP also increased phosphorylated AKT expression in FLS. When Ly294002 was added with GRP, it prevented the GRP-induced increased cell invasiveness (p < 0.001). These data suggest that GRPR expression in FLS and that exogenous GRP are able to activate FLS invasion. This effect occurs at least in part through the AKT activation. Therefore, understanding of the GRP/GRPR pathway could be relevant in the development of FLS-targeted therapy for RA.
Introduction
Rheumatoid arthritis (RA) is a common chronic autoimmune disease in which joint damage is associated with a chronic synovitis characterized by hyperplastic synovial tissue. The fibroblast-like synoviocytes (FLS) has a central role in disease pathogenesis and joint damage [1, 2] .
FLS in the arthritic joint environment is altered to a tumor-like behavior, such as insensibility to undergo apoptosis, increased proliferation, enhanced migratory and invasive capabilities. FLS have been shown to play a pivotal role in initiating and perpetuating joint inflammation and in contributing with cartilage and bone destruction [2] .
FLS invasive properties in vitro have been correlated to radiographic erosive changes and histological joint damage in RA patients [3] . Erosive changes and joint damage correlate with poor outcomes, including increased disability and joint deformities. Hence, inhibition of FLS invasiveness could lead to improved RA outcomes [3] .
Several neuropeptides have been investigated concerning their potential involvement in RA, including substance P, vasoactive intestinal peptide, neuropeptide Y [4] . Another neuropeptide studied is the gastrin-releasing peptide (GRP), which present different biological activities as neuroendocrine regulation, gastrointestinal secretion, cell proliferation [5] . In addition, GRP plays an important role in development and regulation of the immune response by acting in immune cells that express GRPR as lymphocytes, neutrophils and macrophages cells [6, 7] . GRP effects are mediated by gastrin-releasing peptide receptor (GRPR), a member of the G protein coupled receptors [5] . There are evidences that GRPR is found in chondrocytes and synovial membrane of murine experimental arthritis [7, 8] and GRP in joint fluid of RA patients [4] .
RC-3095 is a selective GRPR antagonist with reported anti-inflammatory properties in murine models of gastritis, uveitis and sepsis [5] . Our group has demonstrated anti-inflammatory and reduced joint http://dx.doi.org/10.1016/j.peptides.2017.07.008 Received 2 December 2016; Received in revised form 28 June 2017; Accepted 13 July 2017 damage with RC-3095 in different arthritis experimental models, indicating a possible role of the GRP/GRPR pathway on FLS [6, 9] . However, very little is known about the mechanisms involved in this process.
GRPR signaling is related with activation of PI3K/AKT, a pathway considered as an important mediator of cell survival and proliferation [10] . Previous works have shown that AKT stimulates cell invasiveness, by increasing cell motility and metalloproteinases production [11] . Moreover, it has been demonstrated in human FLS a relation between AKT activation and cell resistance to undergo apoptosis [12] . Based on these observations, the aim of this study was to investigate a possible role of the GRP/GRPR pathway in FLS from collagen-induced arthritis (CIA), as well as the involvement of the PI3K/AKT in GRPR signaling in these cells.
Materials and method
2.1. FLS isolation from mice with CIA and culture DBA1/J mice were induced to CIA as previously described [6] . When animals reached the highest scores, the joints were collected and incubated with collagenase I (1 mg/ml) (Sigma-Aldrich) for 1 h at 37°C. The supernatant was collected and centrifuged at 1100 rpm for 10 min and the pellet was re-suspended in Dulbecco's modified Eagle's medium high glucose (DMEM-HG), supplemented with 15% fetal bovine serum, 1% penicillin-streptomycin and 0.125% gentamicin (Gibco). Afterwards, FLS cells were transferred to a plate for culture at 37°C and 5% CO 2 atmosphere. The initial culture was monitored daily until 70-90% of confluence and then cells were detached with trypsin-EDTA (Gibco) and transferred to a culture flask. FLS were used for experiments after five passages. The purity of FLS cultures was confirmed by flow cytometry (FACSCanto II) using FITC-conjugated antimouse cluster of differentiation (CD) 45 (Sigma-Aldrich), Alexa Fluor 647-conjugated anti-mouse CD248 (Bios Antibodies, Woburn, MA, USA) and APC-conjugated anti-mouse CD90.2 (eBioscience, San Diego, CA, USA) antibodies, as previously tested [13] .
Immunocytochemistry microscopy
FLS were cultured in 6-well plates to 10-20% of confluence, washed with saline buffer phosphate (PBS) and fixed with 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room temperature. For permeabilization and antigen access, cells were incubated with citrate buffer for 1 h at 62.5°C, washed with PBS and incubated with hydrogen peroxide 5% in methanol (Merk). Nonspecific antibody reaction was blocked with 5% skim milk in PBS. Subsequently, the samples were incubated with anti-GRPR (1:100, Abcam) overnight at 4°C in gentle agitation. After washing with PBS, cells were incubated for 1 h with the secondary antibody anti-rabbit HRP-conjugated (1:100, EMD Millipore) at room temperature. The detection was achieved using the DAB-MAP Detection Kit (DAKO). Bright field images were captured with a camera linked to microscope to ascertain protein expression.
Protein extraction
To verify the GRPR expression, FLS were plated (1 × 10 5 cells/ culture flask) and were maintained in culture for 48 h. Then, these cells were washed twice with PBS, scratched and transferred into centrifuge tubes followed by spin centrifugation at 4°C. The supernatant was removed. Cells were mixed with RIPA buffer and the lysate were kept on ice for 10 min followed by a centrifugation at 13000 rpm for 10 min at 4°C. The supernatants were collected and the protein concentration was determined using the Bradford assay.
Immunoblot
Protein extracts (45 μg) were separated by sodium dodecyl sulfatepolyacrilamide gel electrophoresis (SDS-PAGE) 10% and transferred to a polyvinylidene fluoride (PVDF) membrane, in which the remaining binding sites were blocked with 5% skim milk in Tris buffer saline 0.1% Tween-20 (TBST) pH 7.4. Then the membranes were incubated overnight with the specific antibody GRPR (1:500, Abcam (176311, lot GR180204-1)), anti-pAKT (pSer473) (1:1000, Sigma-Aldrich (SAB4300042, lot 511711054)) or anti-GAPDH (1:5000, Sigma-Aldrich (G9545, lot 092M4800 V)) as a constitutive protein for normalization. Band detection was accomplished with anti-IgG rabbit antibodies coupled with horseradish peroxidase (1:80000, Sigma-Aldrich) and visualized by enhanced electrochemiluminescence Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare). Quantification on immunoblot images was performed with the integrated density function of ImageJ (Bethesda). To evaluate pAKT protein expression, cells were plated in the same concentration and after 24 h cells were maintained in serum-free medium overnight. FLS were then treated with GRP (10 μM) for 5-30 min and then protein was extracted to perform WB.
qRT-PCR
To verify GRPR expression, RNA was extracted from FLS in 70-80% of confluence in T25 culture flask and mice liver with RNeasy Mini Kit (Qiagen) according to manufacturer's instruction and quantified with Nanodrop (Thermo Scientific). One microgram of extracted RNA was treated with DNaseI Amplification Grade Kit (Invitrogen). Reverse transcription (RT) was performed using High-capacity cDNA RT Kit (Applied Biosystems). qRT-PCR reactions (20 μl) was performed with SYBR GreenER qPCR SuperMix Universal (Thermo Fisher). Reactions were performed in duplicate in standard conditions with annealing temperature of 60°C for all genes in a QuantStudio 3 qPCR System (Applied Biosystems). GRPR mRNA expression levels were normalized by expression of β-actin as an internal standard. Liver was used as a negative control of GRPR expression. Primers sequences were designed in exon-exon junction to guarantee specificity and avoid DNA contamination: β-actin (forward: 5′-CAAGATCATTGCTCCTCCTGAG-3′, reverse: 5′-GACTCATCGTACTCCTGCTTGC-3′), GRPR (forward: 5′-GTTTCACCCGGGCTTCATCT-3′, reverse: 5′-AACAGGTTTGGCACGTTT CG-3′).
Proliferation assay
FLS proliferation was determined by sulforhodamine B (SRB) assay. Semi-confluent (70-90%) cultures of FLS were harvested with trypsin-EDTA digestion and re-suspended in DMEM-HG. Cells were added to 96-well plates at a density of 5 × 10 3 /well. FLS were allowed to adhere over 24 h, after they were treated with different concentrations of GRP (1 μM-20 μM) (Sigma-Aldrich) or RC-3095 (0.1 μM-10 μM) (SigmaAldrich) for 24, 48 and 72 h at 37°C in 5% CO 2 . The initial solubilization of RC-3095 was done with dimethylsulfoxide (DMSO) (Nuclear) 100% and the subsequent dilutions to 0.1 μM-10 μM were done in DMEM-HG cell medium. Cell monolayers were fixed with 0.1% paraformaldehyde for 15 min. When completely dried, 50 μl of SRB was added for 30 min, washed two times with 1% acetic acid. The bound dye wash dissolved in 10 mM tris base solution and the absorbance of each well measured at 565 nm in a plate spectrophotometer (Spectra Max).
Invasion assay
FLS invasion assay was performed as previously reported [3] with minor modifications. Cells were placed in duplicate at a concentration of 1 × 10 5 cells in 500 μl in the upper compartment of the Matrigelcoated transwell system (BD Bioscience). GRP (10 μM), RC-3095 (1 μM)
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or Ly294002 (10 μM) (PI3 K inhibitor) were added to the upper compartment. The treatments were added alone or together, in this case, first RC-3095 or Ly294002 were added and after 30 min or 1 h, respectively, GRP treatment was added. DMEM-HG supplemented with 15% SFB was added to the lower compartment as a chemoattractant.
Plates were cultured at 37°C in 5% CO 2 for 24 h. Non-invading cells and the Matrigel layer were removed from the upper surface of inserts with swabs and the invading cells on the lower surface were stained with Crystal Violet. The total area of inserts was photographed using a camera coupled in an inverted microscope (Olympus) and the total number of invading cells was counted with the program Image Pro Express (Media Cybernetics).
Statistical analysis
Data are presented as mean or mean ± standard error of the mean (SEM). Statistical analysis was performed by using Generalized Estimating Equation (GEE), accounting for repeated measurements on the same cell culture, followed by Bonferroni in SPSS version 18.0. Statistical difference was considered when p < 0.05 [14] .
Results

GRPR is expressed by FLS
GRPR protein was detected in FLS with characteristic punctate membrane pattern by immunocytochemistry (Fig. 1A) . That observation was further confirmed by WB (Fig. 1B) . In addition, qRT-PCR confirmed GRPR mRNA expression in FLS which was 3.8 fold more expressed than liver negative control (quantitative data not shown).
The involvement of GRP and RC-3095 in the FLS behavior
GRP and RC-3095 treatments did not affect FLS proliferation, although higher concentrations of RC-3095 were associated with a trend for higher cytotoxicity. These cytotoxicity seems to be related to the dilution vehicle of RC-3095 (DMSO) once the higher RC-3095 dose (10 μM) presented 0.5% of DMSO, which was used as treatment control and had a similar cell death profile. (Fig. 2A and B) . GRP (10 μM) significantly increased FLS invasion by nearly two-fold compared with untreated cells (p < 0.02), whereas RC-3095 had the opposite effect (p < 0.05) and also prevented the GRP-induced increase in FLS invasiveness (p < 0.0001; Fig. 2C ).
GRP alters PI3K/AKTpathway
AKT has been implicated in regulates mobility and invasiveness in various types of cells [12] . Therefore, we investigated the role of GRP on PI3K/AKT pathway. The GRP increased AKT phosphorylation in 30%, with an effect detectable as early as 10 min (Fig. 3A and B) . Furthermore, we investigated the role of AKT as a cell signaling mediator of the GRP-GRPR effect on FLS invasion. GRP significantly increased FLS invasion. The PI3K/AKT inhibitor, Ly294002 decreased the FLS invasion (p < 0.001; Fig. 3C ), while GRP + Ly294002 prevented the GRP-induced invasion (p < 0.001).
Discussion
FLS have a central role in RA pathogenesis and pannus formation and secrete diverse cytokines, chemokines and matrix metalloproteinases that can induce cartilage and bone erosion [15] .
The in vitro invasive properties of FLS has been shown to correlate with histology damage in rodent models [3] and with radiographic damage in RA [16] . In previous studies we demonstrated the in vivo anti-inflammatory and immunomodulatory effects of RC-3095 by the modulation of GRPR in arthritis mouse model. RC-3095 also reduced joint damage and bone erosions raising the possibility of a direct effect on FLS [7, 9] .
In the present study, we demonstrated for the first time the presence of GRPR in FLS and that GRP/GRPR pathway affects behavior of FLS by increasing its invasiveness through PI3K/AKT signaling. These discoveries provide new insight into the possible mechanisms of the arthritis-ameliorating effect of RC-3095. In the immunologic system some cell lines express GRPR, including macrophages, T cells and neutrophils [6, 7] . GRPR is also expressed in articular chondrocytes and in some cells of the inflammatory infiltrate in mouse models of arthritis [8] .
At the same time, the GRPR agonist (GRP) expression is increased in chondrocytes [8] , in serum and in synovial fluid of patients with RA [4] . In addition, Grimsholm et al. shown that GRP levels correlates with IL-6 concentration in fluid synovial, leading to the interpretation that 
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Peptides 95 (2017) 57-61 this neuropeptide is associated with disease activity in RA [4] . Although little is known about how the release of GRP into synovial fluid occurs, one possibility is that GRP is produced by non-neuronal cells as neutrophils in the synovial tissue [8] . In this study, we observed that GRP exposure resulted in increased FLS invasiveness, whereas RC-3095, a specific GRPR antagonist, could revert this effect, indicating that the GRP/GRPR pathway seems to be involved in the altered behavior of these cells. These results suggest that GRP can activate FLS invasiveness in joints leading to a destruction of cartilage and bone. This is important because a correlation between in vitro invasive properties of FLS with radiographic erosion and damage in patients with RA and with histologic damage in rats with PIA has been described [3] . There are many mechanisms that could be involved in FLS invasiveness stimulated by GRP. One of these may be the AKT pathway activation. We present evidences that GRP treatment could trigger the pAKT on FLS. This pathway induces different effects on the cell, including resistance to apoptosis, enhanced proliferation and invasiveness. Also, AKT activation protects FLS to undergo apoptosis [12] . In parallel it was related that GRP is able to activate phosphorylation of AKT in lung ephitelial cells [10] . This is the first study to demonstrate the relationship between GRP and AKT pathway in FLS invasiveness. Based on that, we can infer that GRP/GRPR signaling on FLS could stimulate invasion and apoptotic resistance. It is tempting to propose that GRP/GRPR is an attractive target to treat rheumatology arthritis.
Conclusion
We have demonstrates GRPR expression in FLS and that exogenous GRP are able to activate FLS invasion through AKT pathway. Since the pathway GRP/GRPR can be a new attractive target to treatment of AR.
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The authors declare that they have no conflict of interest. Fig. 2 . The involvement of GRP and RC-3095 in FLS behavior. 2A) FLS proliferation was determined by SRB assay after treatment with different concentrations of GRP (1-20 μM) (n = 3) and 2B) RC-3095 (0.1-10 μM) (n = 4) and DMSO (0.5%) (n = 4) for 24, 48 and 72 h. 2C) FLS invasion was determined by transwell Matrigel coated (n = 6). GRP (10 μM) significantly increased FLS invasion by nearly two-fold (5356 ± 1027) compared with FLS (288 ± 532), whereas RC-3095 (1 μM) completely prevented. Bars represent mean ± SEM; a) p < 0.02 versus GRP; p < 0.05 versus RC-3095; b) p < 0.001 versus GRP; c) p < 0.001 versus GRP + RC-3095. Data were analyzed by generalized estimating equation (GEE), followed by Bonferroni statistical test. GRP = gastrin-releasing peptide; FLS = fibroblast-like synoviocytes. Fig. 3 . Effect of GRP in PI3K/AKT pathway. 3A) Immunoblot of pAKT after treatment with GRP in different times in FLS. GRP treatment increased expression of pAKT in time dependent way (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 versus CO. Bars represent mean ± SEM. 3B) FLS invasion assay (n = 4). GRP (10 μM) significantly increased FLS invasion compared with untreated cells, whereas Ly294002 (10 μM) present opposite effect. Bars represent mean ± SEM. Data were analyzed by generalized estimating equation followed by Bonferroni. a) p < 0.008 versus Ly294002; p < 0.026 versus GRP; b) p < 0.001 versus GRP; c) p < 0.001 versus GRP + Ly294002. Data were analyzed by generalized estimating equation followed by Bonferroni statistical test. GRP = gastrin-releasing peptide; FLS = fibroblast-like synoviocytes.
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